KWF: Call for Validation of Biomarker Candidates 2025
The Dutch Cancer Society (KWF) invites multidisciplinary consortia to clinically validate known cancer biomarkers (TRL5/6) that align with patient-relevant outcomes or treatment responses, aiming for near-future integration into daily clinical practice.
Eligibility Criteria
-
Multidisciplinary consortium with at least 4 participating parties (may include private partners).
-
Biomarkers must already be discovered and not yet validated or accepted clinically.
-
Research type: preclinical/clinical.
-
Cancer type: all types.
-
Early Health Technology Assessment (HTA) component mandatory.
-
Patient engagement throughout project lifecycle required.
-
Projects involving large private partners (>250 FTE) must provide 10% co-financing.
Funding Details
-
Total program budget: €4–6 million.
-
Budget per proposal: €0.8–2 million.
-
Project duration: 2–5 years.
-
Maximum payroll hourly rates: Supportive €85, Project Management €100, Expert €125 (excl. VAT).
Key Deadlines
-
Pre-Proposals Open: March 4, 2025
-
Pre-Proposals Deadline: April 29, 2025 (12:00 noon)
-
Full Proposals Open: June 17, 2025
-
Full Proposals Deadline: September 9, 2025 (12:00 noon)
-
Interviews: November 2025
-
Funding Decision: December 2025
Further Information
For full details and to check the biomarker development phase, visit: Dutch Cancer Society – Biomarker Trajectory Scheme or contact: [email protected]
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023